Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QBS 10072S

Next Previous
Search
Drug Profile

QBS 10072S

Alternative Names: NBQ-72S; QBS'72S; QBS-10072-S

Latest Information Update: 13 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Quadriga BioSciences
  • Class Antineoplastics; Nitrogen mustard compounds
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma
  • No development reported Multiple myeloma; Solid tumours

Most Recent Events

  • 10 Feb 2025 Quadriga BioSciences plans a phase-II trial for Meningeal-carcinomatosis (Metastatic disease) (IV) (NCT06810804)
  • 28 Aug 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV)
  • 22 Dec 2022 Quadriga BioSciences completes a Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease) in Australia (IV) (NCT04430842)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top